Case 3: Distant Metastases in Triple-Positive Breast Cancer
Watch
Case 3: Triple-Positive Metastatic Breast Cancer
Case 2: Novel Agents in Late-Stage Clinical Trials for HER2+ MBC
Case 2: Sequencing Treatments for HER2+ Breast Cancer
Case 2: Adverse Effects of Treatments for HER2+ Breast Cancer
Case 2: Risk Factors for Brain Metastases in HER2+ Breast Cancer
Case 2: Impact of Brain Metastases in HER2+ Breast Cancer
Case 2: Later-Line Treatment of HER2+ Breast Cancer
Case 2: Previously Treated HER2+ Breast Cancer
Case 2: Relapsed/Refractory HR-/HER2+ Breast Cancer
Case 1: Subcutaneous Trastuzumab-Pertuzumab for HER2+ Breast Cancer
Case 1: De-Escalation of Adjuvant Anti-HER2 Therapy for Breast Cancer
Case 1: Adjuvant Trials for HER2+ Breast Cancer
Case 1: Adjuvant Therapy After pCR in Early Stage HER2+ Breast Cancer
Case 1: Adjuvant Treatment for Residual Disease in Early Stage HER2+ Breast Cancer
Case 1: Choosing Therapy for Early Stage HER2+ Breast Cancer
Case 1: Neoadjuvant Therapy for Early-Stage HER2+ Breast Cancer
Case 1: Molecular Testing for HER2+ Breast Cancer
Case 1: Early Stage HER2+ Breast Cancer
Clinical Cases in HER2+ Breast Cancer
Experts in breast oncology review 3 clinical cases of HER2+ breast cancer and discuss individualized treatment approaches for each patient.
BTK Inhibitors Continue to Improve Survival in Mantle Cell Lymphoma
Michael Wang, MD, discusses the role of BTK inhibitors as treatment of patients with mantle cell lymphoma ahead of his presentation at the 2020 SOHO Annual Meeting.
Data Support Use of Tivozanib in Patients With Advanced Renal Cell Carcinoma
Ulka Vaishampayan, MD, discusses the use of tivozanib as treatment of patients with advanced renal cell carcinoma, based on supportive data in the TIVO-3 clinical trial.
Deciding on Rituximab Versus Obinutuzumab in Follicular Lymphoma
John M. Burke, MD, discusses treatment with rituximab versus obinutuzumab in patients with advanced stage follicular lymphoma with high tumor burden.
The Future of ALK+ Non–Small Cell Lung Cancer
Understanding the ALTA-1L Trial
First-Line Treatment Options in ALK+ Lung Cancer
Molecular Testing in ALK+ Non–Small Cell Lung Cancer
Case of a Patient With ALK+ Non–Small Cell Lung Cancer
A 58-Year-Old Woman With ALK+ Non–Small Cell Lung Cancer
Lyudmila Bazhenova, MD, presents the case of a 58-year-old woman with ALK+ non–small cell lung cancer.
Moving Beyond JAK Inhibitors in Myeloproliferative Neoplasms
Naveen Pemmaraju, MD, discusses the need to move beyond JAK inhibition when treating patients with myeloproliferative neoplasms.